Cancer 'survivor-care': I. the α7 nAChR as potential target for chemotherapy-related cognitive impairment

Journal of Clinical Pharmacy and Therapeutics

Volumn 36, Issue 4, 2011, Pages 437-445

  Raffa, R B ^a  

^a TEMPLE UNIVERSITY SCHOOL OF PHARMACY   (United States)

Author keywords

7 nicotinic acetylcholine receptor; cancer chemotherapy; cognitive impair ment; survivor care

Indexed keywords

3 (2,4 DIMETHOXYBENZYLIDENE)ANABASEINE; 4 (5 METHYLOXAZOLEO[4,5-B]PYRIDIN 2 YL) 1,4 DIAZABICYCLO[3.2.2]NONANE); ACETYLCHOLINE; ANTINEOPLASTIC AGENT; BUNGAROTOXIN RECEPTOR; N (3 QUINUCLIDINYL)FURO[2,3 C]PYRIDINE 5 CARBOXAMIDE; NICOTINE; POTASSIUM; QUINUCLIDINE DERIVATIVE; SODIUM; UNCLASSIFIED DRUG;

ADVERSE OUTCOME; ALZHEIMER DISEASE; ANTINEOPLASTIC ACTIVITY; BLOOD BRAIN BARRIER; BRAIN CANCER; BRAIN RADIATION; BREAST CANCER; CALCIUM SIGNALING; CANCER ADJUVANT THERAPY; CANCER CENTER; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVOR; CIGARETTE SMOKING; COGNITION; COGNITIVE DEFECT; COMPARATIVE EFFECTIVENESS; DISEASE MODEL; DRUG EFFICACY; DRUG SAFETY; ELECTROENCEPHALOGRAM; HUMAN; KNOCKOUT MOUSE; LEARNING; LONG TERM MEMORY; MEMORY CONSOLIDATION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATTERN RECOGNITION; POSITRON EMISSION TOMOGRAPHY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SCHIZOPHRENIA; SHORT TERM MEMORY; SOCIAL INTERACTION; SPATIAL MEMORY; STRUCTURE ACTIVITY RELATION; WORKING MEMORY;

ANIMALS; ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; COGNITION DISORDERS; DRUG DELIVERY SYSTEMS; HUMANS; NICOTINIC AGONISTS; RECEPTORS, NICOTINIC; SURVIVORS;

EID: 79960105794     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2010.01208.x     Document Type: Review

References (82)

1. Boyle P, Levin B, (2008) World cancer report 2008. Lyon: World Health Organization, 1-511.
2. Raffa RB, Duong PV, Finney J, et al. (2006) Is 'chemo-fog'/'chemo-brain' caused by cancer chemotherapy? Journal of Clinical Pharmacy and Therapeutics, 31, 129-138.
3. Raffa RB, (2010) Is a picture worth a thousand (forgotten) words?: neuroimaging evidence for the cognitive deficits in 'chemo-fog'/'chemo-brain'. Journal of Clinical Pharmacy and Therapeutics, 35, 1-9.
4. Raffa RB, Tallarida RJ, (2010) Effects on the visual system might contribute to some of the cognitive deficits of cancer chemotherapy-induced 'chemo-fog'. Journal of Clinical Pharmacy and Therapeutics, 35, 249-255.
5. Raffa RB, Tallarida RJ, (2010) Chemo fog: cancer chemotherapy-related cognitive impairment, Vol. 678. New York: Springer & Landes.
6. Raffa RB, (2010) A proposed mechanism for chemotherapy-related cognitive impairment ('chemo-fog'). Journal of Clinical Pharmacy and Therapeutics, in press.
7. Oxman TE, Silberfarb PM, (1980) Serial cognitive testing in cancer patients receiving chemotherapy. American Journal of Psychiatry, 137, 1263-1265. (Pubitemid 10015087)
8. Silberfarb PM, Philibert D, Levine PM, (1980) Psychosocial aspects of neoplastic disease: II. Affective and cognitive effects of chemotherapy in cancer patients. American Journal of Psychiatry, 137, 597-601. (Pubitemid 10107447)
9. Packer RJ, Meadows AT, Rorke LB, Goldwein JL, D'Angio G, (1987) Long-term sequelae of cancer treatment on the central nervous system in childhood. Medical and Pediatric Oncology, 15, 241-253. (Pubitemid 18015658)
10. Copeland DR, Dowell RE Jr, Fletcher JM, et al. (1988) Neuropsychological effects of childhood cancer treatment. Journal of Child Neurology, 3, 53-62. (Pubitemid 18044782)
11. Kramer J, Moore IM, (1989) Late effects of cancer therapy on the central nervous system. Seminars in Oncology Nursing, 5, 22-28.
12. Meyers CA, Scheibel RS, (1990) Early detection and diagnosis of neurobehavioral disorders associated with cancer and its treatment. Oncology (Williston Park), 4, 115-122; Discussion 122, 126-127, 130. (Pubitemid 20251543)
13. Gamis AS, Nesbit ME, (1991) Neuropsychologic (cognitive) disabilities in long-term survivors of childhood cancer. Pediatrician, 18, 11-19. (Pubitemid 20335007)
14. van Dam FS, Schagen SB, Muller MJ, et al. (1998) Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: high-dose versus standard-dose chemotherapy. Journal of the National Cancer Institute, 90, 210-218. (Pubitemid 28114539)
15. Ganz PA, (1998) Cognitive dysfunction following adjuvant treatment of breast cancer: a new dose-limiting toxic effect? Journal of the National Cancer Institute, 90, 182-183. (Pubitemid 28114536)
16. Poorthuis RB, Goriounova NA, Couey JJ, Mansvelder HD, (2009) Nicotinic actions on neuronal networks for cognition: general principles and long-term consequences. Biochemical Pharmacology, 78, 668-676.
17. Levin ED, McClernon FJ, Rezvani AH, (2006) Nicotinic effects on cognitive function: behavioral characterization, pharmacological specification, and anatomic localization. Psychopharmacology (Berl), 184, 523-539. (Pubitemid 43255869)
18. Newhouse PA, Potter A, Singh A, (2004) Effects of nicotinic stimulation on cognitive performance. Current Opinion in Pharmacology, 4, 36-46. (Pubitemid 38145836)
19. Sacco KA, Bannon KL, George TP, (2004) Nicotinic receptor mechanisms and cognition in normal states and neuropsychiatric disorders. Journal of Psychopharmacology, 18, 457-474. (Pubitemid 39665114)
20. Adams CE, Stevens KE, (2007) Evidence for a role of nicotinic acetylcholine receptors in schizophrenia. Frontiers in Bioscience, 12, 4755-4772.
21. Goff DC, Henderson DC, Amico E, (1992) Cigarette smoking in schizophrenia: relationship to psychopathology and medication side effects. American Journal of Psychiatry, 149, 1189-1194.
22. Hughes JR, Hatsukami DK, Mitchell JE, Dahlgren LA, (1986) Prevalence of smoking among psychiatric outpatients. American Journal of Psychiatry, 143, 993-997. (Pubitemid 16073948)
23. Llerena A, de la Rubia A, Penas-Lledo EM, Diaz FJ, de Leon J, (2003) Schizophrenia and tobacco smoking in a Spanish psychiatric hospital. Schizophrenia Research, 60, 313-317. (Pubitemid 36184719)
24. Grant BF, Hasin DS, Chou SP, Stinson FS, Dawson DA, (2004) Nicotine dependence and psychiatric disorders in the United States: results from the national epidemiologic survey on alcohol and related conditions. Archives of General Psychiatry, 61, 1107-1115. (Pubitemid 39463411)
25. Masterson E, O'Shea B, (1984) Smoking and malignancy in schizophrenia. British Journal of Psychiatry, 145, 429-432. (Pubitemid 14044932)
26. Harris JG, Kongs S, Allensworth D, et al. (2004) Effects of nicotine on cognitive deficits in schizophrenia. Neuropsychopharmacology, 29, 1378-1385. (Pubitemid 38780661)
27. Barr RS, Culhane MA, Jubelt LE, et al. (2008) The effects of transdermal nicotine on cognition in nonsmokers with schizophrenia and nonpsychiatric controls. Neuropsychopharmacology, 33, 480-490.
28. Sacco KA, Termine A, Seyal A, et al. (2005) Effects of cigarette smoking on spatial working memory and attentional deficits in schizophrenia: involvement of nicotinic receptor mechanisms. Archives of General Psychiatry, 62, 649-659. (Pubitemid 40973440)
29. Smith RC, Warner-Cohen J, Matute M, et al. (2006) Effects of nicotine nasal spray on cognitive function in schizophrenia. Neuropsychopharmacology, 31, 637-643. (Pubitemid 43276979)
30. Cataldo JK, Prochaska JJ, Glantz SA, (2010) Cigarette smoking is a risk factor for Alzheimer's disease: an analysis controlling for tobacco industry affiliation. Journal of Alzheimer's Disease, 19, 465-480.
31. van Duijn CM, Hofman A, (1991) Relation between nicotine intake and Alzheimer's disease. British Medical Journal, 302, 1491-1494.
32. Peters R, Poulter R, Warner J, Beckett N, Burch L, Bulpitt C, (2008) Smoking, dementia and cognitive decline in the elderly, a systematic review. BMC Geriatrics, 8, 36.
33. Reitz C, den Heijer T, van Duijn C, Hofman A, Breteler MM, (2007) Relation between smoking and risk of dementia and Alzheimer disease: the Rotterdam Study. Neurology, 69, 998-1005. (Pubitemid 47366053)
34. Anstey KJ, von Sanden C, Salim A, O'Kearney R, (2007) Smoking as a risk factor for dementia and cognitive decline: a meta-analysis of prospective studies. American Journal of Epidemiology, 166, 367-378. (Pubitemid 47216800)
35. Martin LF, Kem WR, Freedman R, (2004) Alpha-7 nicotinic receptor agonists: potential new candidates for the treatment of schizophrenia. Psychopharmacology (Berl), 174, 54-64. (Pubitemid 38925091)
36. Tatsumi R, Fujio M, Takanashi S, et al. (2006) (R)-3′-(3- methylbenzo[b]thiophen-5-yl)spiro[1-azabicyclo[2,2,2]octane-3,5′ -oxazolidin]-2′-one, a novel and potent alpha7 nicotinic acetylcholine receptor partial agonist displays cognitive enhancing properties. Journal of Medicinal Chemistry, 49, 4374-4383. (Pubitemid 44036681)
37. Mullen G, Napier J, Balestra M, et al. (2000) (-)-Spiro[1-azabicyclo[2.2. 2]octane-3,5′-oxazolidin-2′-one], a conformationally restricted analogue of acetylcholine, is a highly selective full agonist at the alpha 7 nicotinic acetylcholine receptor. Journal of Medicinal Chemistry, 43, 4045-4050.
38. Thomsen MS, Hansen HH, Timmerman DB, Mikkelsen JD, (2010) Cognitive improvement by activation of alpha7 nicotinic acetylcholine receptors: from animal models to human pathophysiology. Current Pharmaceutical Design, 16, 323-343.
39. Albuquerque EX, Pereira EF, Alkondon M, Rogers SW, (2009) Mammalian nicotinic acetylcholine receptors: from structure to function. Physiological Reviews, 89, 73-120.
40. Dani JA, Bertrand D, (2007) Nicotinic acetylcholine receptors and nicotinic cholinergic mechanisms of the central nervous system. Annual Review of Pharmacology and Toxicology, 47, 699-729.
41. Schapira M, Abagyan R, Totrov M, (2002) Structural model of nicotinic acetylcholine receptor isotypes bound to acetylcholine and nicotine. BMC Structural Biology, 2, 1.
42. Breese CR, Adams C, Logel J, et al. (1997) Comparison of the regional expression of nicotinic acetylcholine receptor alpha7 mRNA and [125I]-alpha-bungarotoxin binding in human postmortem brain. Journal of Comparative Neurology, 387, 385-398. (Pubitemid 27430337)
43. Duffy AM, Zhou P, Milner TA, Pickel VM, (2009) Spatial and intracellular relationships between the alpha7 nicotinic acetylcholine receptor and the vesicular acetylcholine transporter in the prefrontal cortex of rat and mouse. Neuroscience, 161, 1091-1103.
44. Seguela P, Wadiche J, Dineley-Miller K, Dani JA, Patrick JW, (1993) Molecular cloning, functional properties, and distribution of rat brain alpha 7: a nicotinic cation channel highly permeable to calcium. Journal of Neuroscience, 13, 596-604. (Pubitemid 23045143)
45. Bertrand D, Galzi JL, Devillers-Thiery A, Bertrand S, Changeux JP, (1993) Mutations at two distinct sites within the channel domain M2 alter calcium permeability of neuronal alpha 7 nicotinic receptor. Proceedings of the National Academy of Science USA, 90, 6971-6975. (Pubitemid 23222370)
46. Castro NG, Albuquerque EX, (1995) alpha-Bungarotoxin-sensitive hippocampal nicotinic receptor channel has a high calcium permeability. Biophysical Journal, 68, 516-524.
47. Wonnacott S, Barik J, Dickinson J, Jones IW, (2006) Nicotinic receptors modulate transmitter cross talk in the CNS: nicotinic modulation of transmitters. Journal of Molecular Neuroscience, 30, 137-140. (Pubitemid 46035352)
48. Alkondon M, Pereira EF, Cortes WS, Maelicke A, Albuquerque EX, (1997) Choline is a selective agonist of alpha7 nicotinic acetylcholine receptors in the rat brain neurons. European Journal of Neuroscience, 9, 2734-2742. (Pubitemid 28082962)
49. Leiser SC, Bowlby MR, Comery TA, Dunlop J, (2009) A cog in cognition: how the alpha 7 nicotinic acetylcholine receptor is geared towards improving cognitive deficits. Pharmacology and Therapeutics, 122, 302-311.
50. Hoyle E, Genn RF, Fernandes C, Stolerman IP, (2006) Impaired performance of alpha7 nicotinic receptor knockout mice in the five-choice serial reaction time task. Psychopharmacology (Berl), 189, 211-223. (Pubitemid 44691543)
51. Young JW, Crawford N, Kelly JS, et al. (2007) Impaired attention is central to the cognitive deficits observed in alpha 7 deficient mice. European Neuropsychopharmacology, 17, 145-155. (Pubitemid 44802833)
52. Stolerman IP, Chamberlain S, Bizarro L, Fernandes C, Schalkwyk L, (2004) The role of nicotinic receptor alpha 7 subunits in nicotine discrimination. Neuropharmacology, 46, 363-371. (Pubitemid 38223869)
53. Keller JJ, Keller AB, Bowers BJ, Wehner JM, (2005) Performance of alpha7 nicotinic receptor null mutants is impaired in appetitive learning measured in a signaled nose poke task. Behavioral Brain Research, 162, 143-152. (Pubitemid 40726288)
54. Fernandes C, Hoyle E, Dempster E, Schalkwyk LC, Collier DA, (2006) Performance deficit of alpha7 nicotinic receptor knockout mice in a delayed matching-to-place task suggests a mild impairment of working/episodic-like memory. Genes, Brain, and Behavior, 5, 433-440. (Pubitemid 44199563)
55. Lightfoot AP, Kew JN, Skidmore J, (2008) Alpha7 nicotinic acetylcholine receptor agonists and positive allosteric modulators. Progress in Medicinal Chemistry, 46, 131-171.
56. Cincotta SL, Yorek MS, Moschak TM, Lewis SR, Rodefer JS, (2008) Selective nicotinic acetylcholine receptor agonists: potential therapies for neuropsychiatric disorders with cognitive dysfunction. Current Opinion in Investigational Drugs, 9, 47-56.
57. Jensen AA, Frolund B, Liljefors T, Krogsgaard-Larsen P, (2005) Neuronal nicotinic acetylcholine receptors: structural revelations, target identifications, and therapeutic inspirations. Journal of Medicinal Chemistry, 48, 4705-4745. (Pubitemid 41038456)
58. Bunnelle WH, Dart MJ, Schrimpf MR, (2004) Design of ligands for the nicotinic acetylcholine receptors: the quest for selectivity. Current Topics in Medicinal Chemistry, 4, 299-334. (Pubitemid 38849362)
59. Guendisch D, Andrae M, Munoz L, Tilotta MC, (2004) Synthesis and evaluation of phenylcarbamate derivatives as ligands for nicotinic acetylcholine receptors. Bioorganic and Medicinal Chemistry, 12, 4953-4962. (Pubitemid 39164403)
60. Tatsumi R, Seio K, Fujio M, et al. (2004) (+)-3-[2-(Benzo[b]thiophen-2- yl)-2-oxoethyl]-1-azabicyclo[2.2.2]octane as potent agonists for the α7 nicotinic acetylcholine receptor. Bioorganic and Medicinal Chemistry, 14, 3781-3784. (Pubitemid 38760079)
61. Bodnar AL, Cortes-Burgos LA, Cook KK, et al. (2005) Discovery and structure-activity relationship of quinuclidine benzamides as agonists of alpha7 nicotinic acetylcholine receptors. Journal of Medicinal Chemistry, 48, 905-908. (Pubitemid 40270435)
62. Wishka DG, Walker DP, Yates KM, et al. (2006) Discovery of N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide, an agonist of the alpha7 nicotinic acetylcholine receptor, for the potential treatment of cognitive deficits in schizophrenia: synthesis and structure - activity relationship. Journal of Medicinal Chemistry, 49, 4425-4436. (Pubitemid 44036685)
63. Kitagawa H, Takenouchi T, Azuma R, et al. (2003) Safety, pharmacokinetics, and effects on cognitive function of multiple doses of GTS-21 in healthy, male volunteers. Neuropsychopharmacology, 28, 542-551.
64. Biton B, Bergis OE, Galli F, et al. (2007) SSR180711, a novel selective alpha7 nicotinic receptor partial agonist: (1) binding and functional profile. Neuropsychopharmacology, 32, 1-16. (Pubitemid 44967780)
65. Pichat P, Bergis OE, Terranova JP, et al. (2007) SSR180711, a novel selective alpha7 nicotinic receptor partial agonist: (II) efficacy in experimental models predictive of activity against cognitive symptoms of schizophrenia. Neuropsychopharmacology, 32, 17-34. (Pubitemid 44967781)
66. Barak S, Arad M, De Levie A, Black MD, Griebel G, Weiner I, (2009) Pro-cognitive and antipsychotic efficacy of the alpha7 nicotinic partial agonist SSR180711 in pharmacological and neurodevelopmental latent inhibition models of schizophrenia. Neuropsychopharmacology, 34, 1753-1763.
67. Acker BA, Jacobsen EJ, Rogers BN, et al. (2008) Discovery of N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide as an agonist of the alpha7 nicotinic acetylcholine receptor: in vitro and in vivo activity. Bioorganic and Medicinal Chemistry Letters, 18, 3611-3615. (Pubitemid 351787553)
68. Tietje KR, Anderson DJ, Bitner RS, et al. (2008) Preclinical characterization of A-582941: a novel alpha7 neuronal nicotinic receptor agonist with broad spectrum cognition-enhancing properties. CNS Neuroscience and Therapeutics, 14, 65-82.
69. O'Donnell CJ, Peng L, O'Neill BT, et al. (2009) Synthesis and SAR studies of 1,4-diazabicyclo[3.2.2]nonane phenyl carbamates - subtype selective, high affinity alpha7 nicotinic acetylcholine receptor agonists. Bioorganic and Medicinal Chemistry Letters, 19, 4747-4751.
70. O'Donnell CJ, Rogers BN, Bronk BS, et al. (2010) Discovery of 4-(5-methyloxazolo[4,5-b]pyridin-2-yl)-1,4-diazabicyclo[3.2.2]nonane (CP-810,123), a novel alpha 7 nicotinic acetylcholine receptor agonist for the treatment of cognitive disorders in schizophrenia: synthesis, SAR development, and in vivo efficacy in cognition models. Journal of Medicinal Chemistry, 53, 1222-1237.
71. Olincy A, Harris JG, Johnson LL, et al. (2006) Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia. Archives of General Psychiatry, 63, 630-638. (Pubitemid 43848294)
72. Freedman R, Olincy A, Buchanan RW, et al. (2008) Initial phase 2 trial of a nicotinic agonist in schizophrenia. American Journal of Psychiatry, 165, 1040-1047.
73. Dziewczapolski G, Glogowski CM, Masliah E, Heinemann SF, (2009) Deletion of the alpha 7 nicotinic acetylcholine receptor gene improves cognitive deficits and synaptic pathology in a mouse model of Alzheimer's disease. Journal of Neuroscience, 29, 8805-8815.
74. Mazurov A, Hauser T, Miller CH, (2006) Selective alpha7 nicotinic acetylcholine receptor ligands. Current Medicinal Chemistry, 13, 1567-1584. (Pubitemid 43821705)
75. Ferchmin PA, Perez D, Eterovic VA, de Vellis J, (2003) Nicotinic receptors differentially regulate N-methyl-d-aspartate damage in acute hippocampal slices. Journal of Pharmacology and Experimental Therapeutics, 305, 1071-1078. (Pubitemid 36617985)
76. Fujii S, Ji Z, Sumikawa K, (2000) Inactivation of alpha7 ACh receptors and activation of non-alpha7 ACh receptors both contribute to long term potentiation induction in the hippocampal CA1 region. Neuroscience Letters, 286, 134-138. (Pubitemid 30312908)
77. Hu M, Schurdak ME, Puttfarcken PS, El Kouhen R, Gopalakrishnan M, Li J, (2007) High content screen microscopy analysis of A beta 1-42-induced neurite outgrowth reduction in rat primary cortical neurons: neuroprotective effects of alpha 7 neuronal nicotinic acetylcholine receptor ligands. Brain Research, 1151, 227-235. (Pubitemid 46709875)
78. Fenster CP, Hicks JH, Beckman ML, Covernton PJ, Quick MW, Lester RA, (1999) Desensitization of nicotinic receptors in the central nervous system. Annals of the New York Academy of Sciences, 868, 620-623. (Pubitemid 29281174)
79. Mike A, Castro NG, Albuquerque EX, (2000) Choline and acetylcholine have similar kinetic properties of activation and desensitization on the alpha7 nicotinic receptors in rat hippocampal neurons. Brain Research, 882, 155-168.
80. Quick MW, Lester RA, (2002) Desensitization of neuronal nicotinic receptors. Journal of Neurobiology, 53, 457-478. (Pubitemid 35375579)
81. Gay EA, Giniatullin R, Skorinkin A, Yakel JL, (2008) Aromatic residues at position 55 of rat alpha7 nicotinic acetylcholine receptors are critical for maintaining rapid desensitization. Journal of Physiology, 586, 1105-1115. (Pubitemid 351267349)
82. Banerjee P, Samoriski G, Gupta S, (2005) Comments on "Memantine blocks alpha7* nicotinic acetylcholine receptors more potently than N-methyl-d-aspartate receptors in rat hippocampal neurons". Journal of Pharmacology and Experimental Therapeutics, 313, 928-929; author reply 930-933.